Drug · CHEMBL451
CHLORDIAZEPOXIDE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. CHLORDIAZEPOXIDE. Drugs and targets, record CHEMBL451. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL451
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Brand names
- Chlordiazepoxide component of limbitrol, Chlordiazepoxide component of limbitrol ds, Chlordiazepoxide component of menrium, Librelease, Libritabs, Sarlib, Trakipeal, Zeisin
- ChEMBL
- Open Targets' highest stage
- Approval, for 3 of its 5 diseases, from ATC, DailyMed and TTD
- Open Targets
Targets16
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| GABRA1 | GABA-A receptor; anion channel | GABA-A receptor; anion channel positive allosteric modulator | POSITIVE ALLOSTERIC MODULATOR | https://conductscience.org/library/genes/2554 |
| GABRA2 | GABA-A receptor; anion channel | GABA-A receptor; anion channel positive allosteric modulator | POSITIVE ALLOSTERIC MODULATOR | https://conductscience.org/library/genes/2555 |
| GABRA3 | GABA-A receptor; anion channel | GABA-A receptor; anion channel positive allosteric modulator | POSITIVE ALLOSTERIC MODULATOR | https://conductscience.org/library/genes/2556 |
| GABRA4 | GABA-A receptor; anion channel | GABA-A receptor; anion channel positive allosteric modulator | POSITIVE ALLOSTERIC MODULATOR | https://conductscience.org/library/genes/2557 |
| GABRA5 | GABA-A receptor; anion channel | GABA-A receptor; anion channel positive allosteric modulator | POSITIVE ALLOSTERIC MODULATOR | https://conductscience.org/library/genes/2558 |
| GABRA6 | GABA-A receptor; anion channel | GABA-A receptor; anion channel positive allosteric modulator | POSITIVE ALLOSTERIC MODULATOR | https://conductscience.org/library/genes/2559 |
| GABRB1 | GABA-A receptor; anion channel | GABA-A receptor; anion channel positive allosteric modulator | POSITIVE ALLOSTERIC MODULATOR | https://conductscience.org/library/genes/2560 |
| GABRB2 | GABA-A receptor; anion channel | GABA-A receptor; anion channel positive allosteric modulator | POSITIVE ALLOSTERIC MODULATOR | https://conductscience.org/library/genes/2561 |
| GABRB3 | GABA-A receptor; anion channel | GABA-A receptor; anion channel positive allosteric modulator | POSITIVE ALLOSTERIC MODULATOR | https://conductscience.org/library/genes/2562 |
| GABRD | GABA-A receptor; anion channel | GABA-A receptor; anion channel positive allosteric modulator | POSITIVE ALLOSTERIC MODULATOR | https://conductscience.org/library/genes/2563 |
1 to 10 of 16Source ChEMBL
See all 16 targetsDiseases5
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| alcohol withdrawal | Phase 3 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0005433 |
| depressive disorder | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0002050 |
| anxiety disorder | Approval | DailyMed and TTD | 2 | 0 | https://conductscience.org/library/drugs?q=MONDO_0005618 |
| alcohol dependence | Approval | DailyMed | 1 | 0 | https://conductscience.org/library/drugs?q=MONDO_0007079 |
| anxiety | Approval | ATC | 1 | 0 | https://conductscience.org/library/drugs?q=MONDO_0011918 |
Source Open Targets
Trials5
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT01573052 | Gabapentin vs Chlordiazepoxide for Ambulatory Alcohol Withdrawal | Phase 4 | 26 | 2020-08-17 | chlordiazepoxide | Its name | ClinicalTrials.gov |
| NCT00136617 | Outpatient Treatment of Alcohol Withdrawal Syndrome | Phase 3 | 165 | chlordiazepoxide | Its name | ClinicalTrials.gov | |
| NCT00516854 | A Study of the Use of Combination of Anti-cholinergic and Minor Tranquilliser in the Treatment of Non-cardiac Chest Pain - a Double Blind Placebo Controlled Study | 100 | chlordiazepoxide | Its name | ClinicalTrials.gov | ||
| NCT01109030 | Pioglitazone as an Adjunct for Moderate to Severe Depressive Disorder | Phase 2/3 | 50 | chlordiazepoxide | Its name | ClinicalTrials.gov | |
| NCT00855699 | Alcohol Detoxification in Primary Care Treatment (ADEPT) | Phase 4 | 36 | chlordiazepoxide | Its name | ClinicalTrials.gov |
Comparisons in its trials1
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial |
|---|---|---|---|---|
| Chlordiazepoxide vs Gabapentin: serious adverse events | 0 of 9 | 0 of 17 | 26 | NCT01573052 |
Source Trial comparisons
Papers from its trials2
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL451
GET https://conductscience.org/api/drugs/v1/CHEMBL451/targets